Building access to the Regenstrief Institute is currently restricted. More on our coronavirus precautions.
See our coronavirus precautions.

Regenstrief Institute research scientist Noll Campbell, PharmD, M.S., recently contributed to a study that made national headlines and provided more evidence that anticholinergic medications are linked to cognitive decline.

The results from the study, led by researchers at the University of California San Diego School of Medicine, were published in Neurology. The authors concluded that anticholinergics are associated with an increased risk of cognitive decline regardless of the presence of genetic or biomarker risk factors for Alzheimer’s disease.

Dr. Campbell consulted on the study, providing perspective on the data based on similar studies he has been involved with at Regenstrief and Indiana University School of Medicine.  He is listed as an author on the paper.

The past research conducted by Dr. Campbell and his colleagues also provides evidence establishing a link between the common type of medication and cognitive decline. He is now leading a clinical trial to determine if deprescribing anticholinergics improves cognition, which could in turn delay or prevent dementia.

In addition to his role as a research scientist at Regenstrief Institute, Dr. Campbell is an assistant professor of pharmacy practice at the Purdue University College of Pharmacy.

Related Influence

Nov 04, 2021 • Influence
Regenstrief data experts contribute to NEJM, CDC COVID-19 papers
Regenstrief Institute data experts are actively working to further the understanding of COVID-19 through real-world data. In the last week, the Regenstrief chief executive officer and a vice president have been lead authors on papers published in the U.S. Centers for Disease Control and Prevention (CDC)’s Morbidity and Mortality Weekly Report (MMWR). Regenstrief President and Chief Executive Officer Peter Embí, M.D., M.S., is first…
Continue Reading >
Nov 01, 2021 • Influence
Regenstrief scientist highlights benefits of gene-specific approaches to colon cancer surveillance
Regenstrief Research Scientist Jennifer K. Maratt, M.D., M.S., co-authored a commentary in Gastroenterology about the benefits of gene-specific surveillance colonoscopy strategies for Lynch Syndrome, an inherited syndrome that increases the risk for colon cancer. The editorial was published in conjunction with a paper from Columbia University. In that study, researchers created different surveillance strategies for…
Continue Reading >